Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from OmniAb ( (OABI) ) is now available.
On January 30, 2026, OmniAb, Inc.’s board approved amended and restated bylaws that took effect the same day, aligning the company’s governance framework with updated U.S. Securities and Exchange Commission universal proxy rules by stipulating that proxy solicitations for director nominees other than the board’s own must comply with Rule 14a-19. The revisions also tighten and modernize the procedural and disclosure requirements for shareholder director nominations and other business proposals at shareholder meetings—mandating more extensive background and ownership information from proposing shareholders, nominees and related parties—which is likely to strengthen the company’s control over the nomination process and enhance transparency in corporate governance.
The most recent analyst rating on (OABI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OmniAb stock, see the OABI Stock Forecast page.
Spark’s Take on OABI Stock
According to Spark, TipRanks’ AI Analyst, OABI is a Neutral.
OmniAb’s overall stock score reflects significant financial challenges, with negative revenue growth and substantial losses. However, positive technical indicators and strategic initiatives provide some optimism. The company’s valuation remains a concern due to ongoing losses.
To see Spark’s full report on OABI stock, click here.
More about OmniAb
OmniAb, Inc. operates in the biopharmaceutical technology sector, offering antibody discovery platforms and related services that support pharmaceutical and biotechnology companies in developing antibody-based therapies.
Average Trading Volume: 514,138
Technical Sentiment Signal: Sell
Current Market Cap: $266.3M
See more insights into OABI stock on TipRanks’ Stock Analysis page.